F. Hoffmann-La Roche: Restructuring - An Exclusive Interview with Eric de La Fortelle




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: F. Hoffmann-La Roche: Restructuring - An Exclusive Interview with Eric de La Fortelle
Released on: May 01, 2007. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this exclusive interview, Fintan Walton talks to Eric de La Fortelle, Global Head, External Research and Technology, F.
  • Summary
  • Participants
  • Company
In this exclusive interview, Fintan Walton talks to Eric de La Fortelle, Global Head, External Research and Technology, F. Hoffmann-La Roche, about the global restructuring of Roche’s research and development activities, which is due to be implemented on 2 July 2007. Eric explains that Roche has taken the decision to improve its R&D model at a time of strength, when its financial results are proving excellent, in order to adapt to a changing environment in which demands are increasing from both patients and regulators.

In the interview, Eric describes how Roche R&D will be organised into five Disease Biology Areas (DBAs), and how these DBAs will be managed. He also explains the research and development tensions that can be resolved by this new model. Just how these changes will affect partnering with Roche is discussed as well, highlighting the integrated role that the Roche Pharma Partnering group, to be led by the incoming Dan Zabrowski, will have with the new DBAs.
Dr Eric de La Fortelle is Global Head, External Research and Technology, for Roche Pharma Partnering in Basel, Switzerland. He heads a group with a mandate to find and establish contracts, and to manage global alliances with companies offering discovery-stage products and innovative technologies.

Eric is a scientist by training, with contributions in the field of structure-based drug design (the determination of 3D-structures of protein targets by X-ray crystallography).

He has extensive experience of negotiating Pharma/Biotech alliances (both from the Biotech and the Pharma side). He holds a PhD in Physics from Paris XI University, and an MBA from INSEAD.
F. Hoffmann-La Roche
F. Hoffmann–La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange.

The company headquarters are located in Basel and the company has many sites around the world - including: Nutley, NJ, Palo Alto, California, Pleasanton, Branchburg, Fishers, Indiana, Florence, South Carolina, Boulder, Colorado and Ponce, Puerto Rico in the US, Welwyn Garden City and Burgess Hill in the UK, Clarecastle in Ireland, Mannheim and Penzberg in Germany, and Shanghai in China.

The company also owns the American biotechnology company Genentech, which is a wholly owned subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals.